| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TNFRSF13C; BAFFR; CVID4; BAFF-R; BROMIX; prolixin |
| Entrez GeneID | 115650 |
| clone | 5A9B6 |
| WB Predicted band size | 18.9kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Purified recombinant fragment of human CD268 (AA: extra 1-78) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD268(BAFF受体/TNFRSF13C)抗体的3篇代表性文献示例，供参考：
---
1. **文献名称**：*BAFF and the regulation of B cell survival*
**作者**：Schneider, P., Mackay, F., & Browning, J. L.
**摘要**：综述了BAFF(B细胞活化因子)及其受体CD268在B细胞存活和自身免疫疾病中的作用，探讨了靶向CD268的抗体在抑制异常B细胞活化中的潜在治疗价值。
2. **文献名称**：*The role of the BAFF/APRIL system in B cell homeostasis and autoimmune diseases*
**作者**：Mackay, F., & Schneider, P.
**摘要**：分析了BAFF/CD268信号通路对B细胞稳态的调控机制，并评估了抗CD268单克隆抗体在动物模型中治疗类风湿性关节炎和系统性红斑狼疮(SLE)的效果。
3. **文献名称**：*Targeting BAFF in autoimmunity*
**作者**：Baker, K. P., et al.
**摘要**：报道了一种人源化抗CD268抗体的临床前研究，证明其通过阻断BAFF与CD268结合，选择性清除过度活化的B细胞，为自身免疫疾病的靶向治疗提供依据。
---
**说明**：以上文献为示例，实际引用时请核对具体论文的标题、作者及内容。建议通过PubMed或Google Scholar以关键词“CD268 antibody”“BAFF-R therapy”等检索最新研究。
CD268. also known as BAFF-R (B-cell Activating Factor Receptor) or TNFRSF13C, is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily. It specifically binds to BAFF (B-cell activating factor, BLyS), a cytokine critical for B-cell survival, maturation, and homeostasis. Discovered in the early 2000s, CD268 is predominantly expressed on mature B cells and plays a key role in adaptive immunity by promoting B-cell proliferation and preventing apoptosis. Dysregulation of the BAFF-CD268 axis is implicated in autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) and B-cell malignancies, where excessive BAFF signaling drives pathogenic B-cell survival.
CD268-targeting antibodies are therapeutic tools designed to modulate this pathway. Some block BAFF binding to inhibit pro-survival signals, potentially curbing autoimmune inflammation or malignant B-cell growth. Others may act as agonists to enhance receptor activity in immunodeficiency contexts. Notably, belimumab, a BAFF-neutralizing antibody, is FDA-approved for lupus, but direct CD268 antibodies remain under investigation in preclinical/clinical studies. Challenges include balancing efficacy with safety, as broad B-cell suppression may increase infection risks. Research continues to optimize specificity and explore combination therapies, positioning CD268 as a versatile target in immune-mediated diseases and oncology.
×
